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ABSTRACT
Background To assess the implication of a possible
continuation of the decline in ischaemic heart disease
(IHD) mortality in the future.
Methods Annual rates of decline in IHD mortality from
1980e2005 were determined for the national
populations of the Netherlands, UK, France and four
Nordic countries through regression analysis and used to
extrapolate mortality rates until 2030. Through
cause-elimination life tables we determined the impact
of IHD on life expectancy at birth.
Results In all countries, IHD mortality rates among both
sexes declined incessantly until 2005. Age-adjusted
mortality rates would have declined by about 50% in
2030 compared to 2005 if past trends were to continue.
The impact of IHD on life expectancy at birth would
decline by about 25e50% in most populations. The
absolute numbers of IHD deaths would decline slowly or
even increase in some countries mainly because of
population ageing.
Conclusions If current IHD mortality trends continued,
IHD would lose much of its importance as a cause of
premature death in the near future. As the incidence and
disabling impact of IHD might decline much less,
prevention of IHD-related disability instead of mortality
may become increasingly important in the future.
Mortality from ischaemic heart disease (IHD) had
fallen substantially in the past decades, even
though it is still the leading cause of death in
Europe.1 Previous studies have documented the
steady and substantial decline of IHD mortality in
western Europe over recent decades,2 3 especially
the past 30 years,4 with greater decreases in some
than in other countries.5 Causes of the decline are
complex but changes in diet appear to play a major
role. The more recent declines in western Europe
also reﬂect improvements in modern cardiovascular
treatment.4 Also, outside Europe the IHD decline is
associated both with trends in classic risk factors
and with improvements in medical treatments.6
However, the WHOMONICA project showed that
an important part of the decline in IHD mortality
remains unexplained even after control for classical
risk factors.7 8 Part of the unexplained trends might
be due to changes in other determinants, such as
socioeconomic status, early life conditions or
different combinations of these.8
The decline in IHD mortality rates does not
necessarily mean a decline in IHD absolute number
of deaths. The absolute number of IHD deaths
might continue to increase due to ageing of the
European population.9e11
The main aim of this study is to assess the
implication of a possible continuation of the decline
in mortality from IHD in the future based on
recent mortality trends. We will assess what could
be a future trend in IHD mortality and its impact
on life expectancy on men and women in seven
European countries up to 2030. We also aim to
explore the future number of absolute deaths from
IHD taking into account population ageing. In
addition, we aim to assess whether IHD mortality
trends would be converging or diverging among
European populations if recent trends in IHD
mortality in these countries were to continue in the
next 25 years.
It should be emphasised that our study is not
a prediction of future trends, but an exploration of
possible future trends based on the extrapolation of
past trends. This extrapolation provides a baseline
scenario for scenario studies that, by using disease-
speciﬁc population models, might aim to evaluate
the speciﬁc impact of future changes in the preva-
lence of one or more IHD risk factors (eg, smoking,
obesity and hypertension) or in the treatment of
IHD patients.
MATERIALS AND METHODS
We obtained data for Denmark, Finland, France, the
Netherlands, Norway, Sweden, and England and
Wales. We selected these countries because they are
heterogeneous enough yet have a comparable level
of wealth and socioeconomic structure, and their
long-term mortality and population data are
known to be of good quality.12 13
For each country, we obtained data on the
national number of deaths from IHD (International
Classiﬁcation of Diseases (ICD) codes 410e414 for
ICD-8 and ICD-9, and I20eI25 for ICD-10) by
gender and 5-year age groups for the years
1980e2005.14 15 In a previous study, national
contact persons extracted detailed mortality data
ﬁles, with pre-speciﬁed formats, from national
cause of death registries.15 In more recent analyses,
additional data for years after 2000 were obtained
from Eurostat (http://epp.eurostat.ec.europa.eu/)
or national sources.16 Corresponding numbers of
population at risk were supplied by national
contact persons, or derived from Eurostat, on the
basis of data from population censuses or popula-
tion registers. As the study period included
different revisions of the WHO ICD, we adjusted
for effects of coding changes using a regression-
based method that is reported elsewhere.14
There are no Eurostat data on France and
England and Wales, but instead on ‘France metro-
politan’ and on UK. Therefore, the historical
national data for England and Wales and France
were transformed into data for UK and France
metropolitan by applying age and sex-speciﬁc
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correction factors. These correction factors were derived from
a comparison of IHD mortality rates that could be estimated for
each area in 1995.
To describe trends in IHD mortality between 1980 and 2005,
sex-speciﬁc age-standardised mortality rates were calculated
using direct standardisation, taking the total EU25 (the Euro-
pean Union comprising 25 member states) population by 5-year
age group in 2005 as the standard population (http://epp.euro-
stat.ec.europa.eu/). In addition, we estimated sex-speciﬁc and
country-speciﬁc annual mortality changes (%) over the period
1980e2005 by means of age-period log-linear regression analysis.
The dependent variable was the number of deaths with the
person-years at risk (estimated by the average population) as
offset variable. We used age by 5-year age groups (from 0 to 80+)
(categorical) and single calendar year (continuous) as indepen-
dent variables. Annual mortality changes (%) were calculated by
the formula: 100*(exp (b)1), in which b is the parameter esti-
mate of the calendar year variable.
To project age, sex and country-speciﬁc mortality rates for the
years 2010, 2015, 2020, 2025 and 2030, we applied the estimated
annual changes (%) in mortality in the period 1980e2005 for all
age groups combined to average national age-speciﬁc mortality
rates in 2000e2005 (average year used as t0). We used the
following formula (country and sex-speciﬁc):
nM
t0þ t
x ¼ nMt0x ðncx þ 1Þt:
Where c* is the annual decline (exp(b)1) for all age groups
multiplied by a ratio expressing the annual decline in the age
groups 40e59, 60e79 and 80+ year relative to the annual trends
for all age groups (unweighted average over all countries).
Thus, we assumed that the mortality trends in the past
25 years (from 1980e2005) would continue for the coming
25 years; thereby, taking into account age differences in the
mortality decline. Thus, future trend predictions are based solely
on past mortality trends.
Future IHD mortality numbers were estimated by applying
the future sex and age-speciﬁc rates to the projected sex and
age-speciﬁc population sizes for the different countries up to
2030. These future population numbers have been obtained
from Eurostat (baseline variant), except for Norway for which
the data have been obtained from Statistics Norway
(medium national growth variant) (http://statbank.ssb.no/
statistikkbanken).
The impact of IHD on life expectancy is assessed by means of
the potential gain in life expectancy (PGLE)da standard
measure derived from the cause-elimination life table.17 For the
years 2005 and 2030, we prepared cause-elimination life tables
using projected all-cause mortality rates and projected IHD
mortality rates for each respective projection year. All-cause
mortality rates were obtained from the international Human
Mortality Database (http://www.mortality.org/). These rates
were projected using the same procedures as for IHD.
RESULTS
Figure 1 shows changes in mortality rates from IHD in seven
European countries according to year of death from 1980e2005.
The annual rate of change over the period 1980e2050 by
country and sex is given in table 1. In all seven European
countries, IHD mortality rates declined for both men and
women. In each country, relative declines were slightly larger for
men (inter-country range 2.70 to 4.17%) than for women
(range 1.89 to 3.67%). Relatively strong declines were
observed in the Netherlands, Sweden and Denmark. The rank
order of decline in countries remained about similar over time for
both sexes. The decline persisted until 2005 with no consistent
evidence for a deceleration.
Table 2 summarises the projected IHD mortality rates and
PGLE for IHD in seven European countries in 2030. In all seven
European countries, age-adjusted mortality rates would have
substantially declined in 2030 compared to 2005 if past trends
were to continue. For most populations, the rate ratios
comparing 2030 to 2005 are close to 0.50, indicating about 50%
decline in mortality rates if past trends were to continue.
Declines larger than 50% are projected for men and women in
Denmark, Sweden and the Netherlands, and for men in the UK.
Although the seven European countries differ in the pattern of
decline over time, they would show some convergence in IHD
mortality rates until 2030. For example, the low French
mortality levels of 2005 would be reached by the Dutch and the
Danish in 2030. Because mortality rates of men showed slightly
stronger declines than rate of women in all countries there
would be a convergence in mortality from IHD among men and
women in most countries.
When IHD would be eliminated, life expectancy at birth
would increase by 1 (France) to 4 years (Finland) for both men
and women. In our projection, the PGLE will decrease between
2005 and 2030 for both men and women in all countries. The
declines in PGLE are generally smaller than those for age-
adjusted mortality rates because estimates for PGLE in 2030 are
positively inﬂuenced by the higher levels of total life expectancy
in 2030 (due to decreasing levels of all-cause mortality). Among
men, the PGLE would decline between 2005 and 2030 by
25e50% in most countries, with smaller (10%) declines in
France. Similar declines are projected for women, although with
greater variability between countries.
Figure 2 shows the projected absolute number of deaths from
IHD for men and women from 2005 to 2030. In all seven
countries, absolute number of IHD deaths will not substantially
decrease, and in some cases even increase, despite the steady
decline in mortality rates.
DISCUSSION
Summary
The dramatic and persistent decline in IHD mortality observed
for the 1980s and 1990s was found to continue at an undimin-
ished pace until 2005 in each of the seven European countries
included in this study. If this decline were to continue, IHD
mortality rates would reach unprecedented low levels. In most
populations, age-adjusted mortality rates would have declined
by about 50% in 2030 compared to 2005. The impact of IHD on
life expectancy at birth would decline by about 25e50% in most
populations. The absolute numbers of IHD deaths would decline
slowly or even increase in some countries.
While IHD mortality rates have halved over recent decades,
the total numbers of deaths have not declined correspondingly.
Future trends in absolute numbers of death are determined in
part by the growth of the national populations but especially
by the ageing of these populations. Especially after the year
2020, when the post-war ‘baby boom’ generation will reach old
age, the numbers of deaths were projected to increase. The
future burden of IHD mortality will affect increasingly older
groups.18
Evaluation of data and methods
The national mortality and population data used in this study
come from data sources that are known to be good quality.12 13 19
Any problems with the coverage or completeness of death
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registries or population registrations are likely to have no or
minimal effects on our results. We made an extra-ordinary effort
to deal with ICD and other coding-related changes that can affect
the study of mortality trends from IHD. Even though some
residual effects of coding problems could not be excluded, we
expect that these problems did not affect the results to any
substantial extent.14 15
Although the extrapolation of past trends is not the only
means of making projections, explorations of the future should
also be fairly realistically based on trends observed in the past.
We followed recommendations of Wilmoth10 and the European
Association for Population Studies20 to use observed trends in
the past as the basis to make projections for the future. The
main limitation to extrapolation-based projections is that they
cannot take into account unforeseen changes in future mortality
decline (accelerations, decelerations or even stagnations) and
they do explicitly take into account speciﬁc factors. Our
projections should be taken as a basis for more speciﬁc scenario
studies that would focus on the effect of trends in speciﬁc risk
factors or healthcare.21 Thus, the trends that we projected may
provide a new perspective to appreciate the implications of
recently observed mortality trends and the likely impact of new
epidemiological trends and innovations in healthcare.
Explanation of past trends
The substantial reduction in IHD mortality is likely to be
attributable to declines in both case-fatality rates and in inci-
dence rates.22 Declines in the incidence of IHD have been
fostered by the promotion of primary prevention in the general
population resulting in improvement of lifestyle factors, such as
cigarette smoking, dietary habits (such as consumption of fruit
and vegetables) and physical activity.23 The decreasing case-
fatality of IHD in turn, could be attributed to the medical
interventions aimed to increase survival after acute events and
Table 1 Annual changes (%) and 95% CI in ischaemic heart disease
mortality over the period 1980e2005 in seven European countries by
gender
Country Men Women
Denmark 4.17 (4.25 to 4.10) 3.67 (3.75 to 3.59)
UK 3.40 (3.41 to 3.38) 2.72 (2.74 to 2.70)
Finland 3.30 (3.35 to 3.24) 1.89 (1.95 to 1.82)
France 2.70 (2.73 to 2.67) 2.57 (2.60 to 2.54)
Netherlands 4.11 (4.15 to 4.06) 3.53 (3.58 to 3.47)
Norway 3.46 (3.53 to 3.40) 2.56 (2.64 to 2.48)
Sweden 3.97 (4.01 to 3.93) 3.64 (3.69 to 3.59)0
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Figure 1 Age-standardised ischaemic heart disease (IHD) mortality
rates (per 100 000) in seven European countries by sex: 1980e2005*y.
*Data for Denmark until 2001. yCorresponding estimates of annual
mortality changes (%) for men (women) are for Denmark 4.17 (3.67),
UK 3.40 (2.72), Finland 3.30 (1.89), France (Metropolitan) 2.70
(2.57), the Netherlands 4.11 (3.53), Norway 3.46 (2.56) and
Sweden 3.97 (3.64).
Table 2 Age standardised ischaemic heart disease mortality rates (per 100 000) and potential gain in life expectancy (PGLE)(years) projections in
seven European countries by gender from 2005e2030
Year
Country
Denmark UK Finland France Netherlands Norway Sweden
Men
Mortality rates 2005 209.25 267.40 313.07 93.64 133.74 182.20 230.93
2030 90.13 120.22 163.25 55.55 61.43 102.74 104.70
Ratio 2030/2005* 0.43 0.45 0.52 0.59 0.46 0.56 0.45
PGLE 2005 1.97 3.31 3.98 1.17 1.38 2.12 2.85
2030 1.01 2.23 3.03 1.05 0.76 1.60 1.86
Ratio 2030/2005 0.51 0.67 0.76 0.90 0.55 0.75 0.65
Women
Mortality rates 2005 119.51 146.00 171.96 42.38 65.38 92.42 121.31
2030 52.52 69.76 121.52 26.36 31.22 61.91 55.44
Ratio 2030/2005 0.44 0.48 0.71 0.62 0.48 0.67 0.46
PGLE 2005 1.76 2.35 4.10 0.98 1.05 1.79 2.34
2030 0.77 1.44 3.62 0.84 0.49 1.42 1.29
Ratio 2030/2005 0.44 0.61 0.88 0.86 0.47 0.79 0.55
For Denmark, the values for 2005 are not observed but projected.
*The figure of 2030 divided by the related figure in 2005.
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secondary prevention aimed to prolong life of the patients with
diagnosed disease.22
It is difﬁcult to quantify the relative contributions of risk
factor changes and effective medical interventions because
favourable trends in both have occurred simultaneously. Their
relative contributions may vary widely from country to country
and from time to time.24 Evidence is accumulating that the
early declines in IHD mortality are, to a large extent, due to
changes in diet and other lifestyle factors, whereas the more
recent declines are mostly due to improvements in modern
cardiovascular treatment.4
A noteworthy ﬁnding is that the relative decline in IHD
mortality tended to be weaker in France compared to other
countries especially among men. In 1980, France had much
lower mortality rates than most other countries especially for
men. These lower mortality rates compared to northern Euro-
pean countries constitutes the ‘French paradox’ or ‘Mediterra-
nean’ paradoxdas it also applies to other Southern European
countries.25 The causes of the north-south contrast in IHD
mortality are yet poorly understood, but may involve patterns
of wine consumption, dietary habits and underlying patterns of
behaviour.25 From our analysis, it appears the relative advantage
that France derives from these factors may gradually diminish in
the near future.
Determinants of future trends
Only time will tell whether these factors will together ensure
a similar pace of decline in IHD mortality until 2030. Future
declines in IHD mortality would be expected to follow from the
introduction of new treatments and increased uptake of existing
Figure 2 Absolute number of deaths
(1000s) from ischaemic heart disease
(IHD) in seven European countries by
country and sex: 2005e2030. For
Denmark, the values for 2005 are not
observed but projected.
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treatments, both in the treatment for acute IHD and in the long-
term care for IHD survivors. However, medical treatment may
reach limits especially among the oldest because of persisting
problems such as high levels of co-morbidity. Limitations to
efﬁcacious live-saving treatment of older IHD patients is
reﬂected by much slower rates of decline of IHD mortality
among 80 years old since 1980, which were taken into account
in our projections until 2030.
Further improvement with regards to lifestyle might occur
thanks to growing awareness on the importance of relevant
behaviours among more well-informed and better educated
populations of the future. For example, this may stimulate
further declines in smoking prevalence, which is likely to be
backed up by far-reaching tobacco control policies. On the other
hand, other risk factors may become more important, such as
diabetes mellitus.26 27 However, the envisaged effect on IHD
mortality may be counteracted by efﬁcacious medical treatment
of diabetic people; thus, reducing case death rates. For example,
evidence from clinical trials supports the value of lipid-lowering
treatment for patients with diabetes mellitus.20
The increasing prevalence of diabetes mellitus is driven largely
by increasing prevalence rates of obesity and overweight29 with
its increased risk of death from IHD.28 Obesity prevalence is
expected to further increase in the in the near future.29 30
Therefore, in further calculations, we estimated what would
happen to future IHD mortality trends if (a) recent trends in
average body mass index (BMI) levels in western Europe would
continue between 2005 and 203031 and (b) the relationship
between BMI and IHD mortality as observed in recent studies
would also persist in the future.32 We found that the effect
would be to increase IHD mortality by about 10% between 2005
and 2030. This increase is important but relatively small
compared to the 50% declines in IHD mortality rates that we
projected based on trends in IHD mortality in the past 25 years.
The decline in IHD mortality in the future is unlikely to be
paralleled by a similar decline in IHD incidence, especially when
incidence rates will be affected by the obesity epidemic.
Declining case-fatality rates, thanks to improved treatment of
IHD patients, are likely to make substantial contribution to
falling mortality rates. As a result, while IHD mortality is likely
to decline, especially at younger ages, the age-speciﬁc prevalence
of IHD among elderly populations may increase.
Implications of projected future trends
The contrast between declining age-speciﬁc mortality rates and
constant absolute numbers of deaths raises question on how to
evaluate the importance of IHD as a cause of death. In any
generation, mortality is inevitable; still many will die of IHD.
However, the main issue is not whether people will die but until
what age they can expect to live. Similarly, the importance of
IHD as a cause of death should not only be measured by the
number of people dying from this disease but also by taking into
account the number of years of life that they lose due to death
from IHD. We observed that the effect of IHD on life expectancy
would decline by about 25e50% in most populations. IHD
mortality rates would decline especially at younger ages; thus,
transforming IHD increasing more into an old-age disease with
a limited impact on life expectancy at birth.
The observed sharp decline in mortality might lead one to
expect a decrease in healthcare utilisation. However, in reality,
healthcare providers are facing increases in demand.33 As with
the trends in absolute number of IHD deaths, part of this
increase in hospitalisations will be prompted by the ageing of
‘baby boomers’.34 Generally, the ageing of the population and
the demographic changes projected for 2030 will have a major
impact on the prevalence of and cost of care for IHD35 with
different slopes between populations.36 Moreover, it has been
suggested that the increased survival of IHD patients may result
in an increase in the incidence and prevalence associated to other
atherosclerosis related cardiovascular diseasedfor instance,
cerebrovascular disease. The literature on this topic is not
conclusive and Peeters rejected this hypothesis.37
In conclusion, if current IHD mortality trends would
continue, IHD mortality would lose much of its importance in
the future and become mainly a death related to old age in the
highly developed Western European countries. On the other
hand, the prevalence of IHD is likely to increase and so is the
related demand for healthcare. Therefore, the priority of
prevention and treatment of IHD will have to be shifted from
prevention of death to prevention of disability.
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